Expression and clinical value of NRP-1 in hepatocellular carcinoma

doi:10.3760/cma.j.issn.1673-422X.2017.06.007

Abstract

Abstract: ObjectiveTo determine the expression and clinical value of neuropilin1 (NRP1) in hepatocellular carcinoma (HCC). MethodsOne hundred and fiftyone cases of HCC tissues and 89 cases of healthy liver tissues were chosen to compare the expression of NRP1 by immunohistochemistry. Then the relationships between different clinical factors and the expression of NRP1 were analyzed by univariate and multivariate statistical analysis. Moreover, the survival rates were compared by survival analysis between different expressions of NRP1 in HCC patients. ResultsEleven cases were lost to followup or died for non HCC disease, and the effective cases in the final study were 140 cases. The positive expression rates of NRP1 in HCC and normal liver tissues were 65.00% and 35.96% respectively, and the difference was statistically significant (χ2=18.843, P<0.001). According to the expression level of NRP1, 140 patients with HCC were divided into negative expression group (n=49) and positive expression group (n=91). Univariate analysis showed that the expression of NRP1 in HCC was correlated with tumor number (χ2=8.025, P=0.005), TNM stage (χ2=26.467, P<0.001), differentiation degree (χ2=15.296, P<0.001), portal vein invasion (χ2=9.054, P=0.003) and hepatic vein invasion (χ2=5.928, P=0.015). Multivariate statistical analysis showed that TNM stage (OR=1.392, 95%CI: 1.1211.730, χ2=8.950, P=0.003), differentiation degree (OR=1.469, 95%CI: 1.1021.958, χ2=6.862, P=0.009), portal vein invasion (OR=1.829, 95%CI: 1.1572.893, χ2=6.665, P=0.010) and hepatic vein invasion (OR=2.161, 95%CI: 1.1723.987, χ2=6.084, P=0.014) were important factors for NRP1 expression. The median survival time of NRP1 negative HCC patients was significantly longer than that of positive group (44 months vs. 23 months), and the difference was statistically significant (χ2=21.922, P<0.001). ConclusionNRP1 is overexpression in HCC tissue and related to the malignant progress of HCC, and this suggests poor prognosis in patients with HCC.

Key words: Carcinoma, hepatocellular, Neuropilin-1, Survival rate, Gene expression

Chen Yu, Ji Hongchen, Cao Dayong, Li Xiao. Expression and clinical value of NRP-1 in hepatocellular carcinoma[J]. Journal of International Oncology, 2017, 44(6): 428-.

References

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262. ［2］ Li D, Kang J, Golas BJ, et al. Minimally invasive local therapies for liver cancer［J］. Cancer Biol Med, 2014, 11(4): 217-236. DOI: 10.7497/j.issn.20953941.2014.04.001. ［3］ Buendia MA, Neuveut C. Hepatocellular carcinoma［J］. Cold Spring Harb Perspect Med, 2015, 5(2): a021444. DOI: 10.1101/cshperspect.a021444. ［4］ Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations［J］. Best Pract Res Clin Gastroenterol, 2014, 28(5): 843-853. DOI: 10.1016/j.bpg.2014.07.018. ［5］ Chung AS, Ferrara N. Developmental and pathological angiogenesis［J］. Annu Rev Cell Dev Biol, 2011, 27: 563-584. DOI: 10.1146/annurevcellbio092910154002. ［6］ Risau W. Mechanisms of angiogenesis［J］. Nature, 1997, 386(6626): 671-674. DOI: 10.1038/386671a0. ［7］ Robinson SD, Reynolds LE, Kostourou V, et al. Alphav beta3 integrin limits the contribution of neuropilin1 to vascular endothelial growth factorinduced angiogenesis［J］. J Biol Chem, 2009, 284(49): 33966-33981. DOI: 10.1074/jbc.M109.030700. ［8］ Narayanan N, Su N, Bedard P. Inhibitory and stimulatory effects of fluoride on the calcium pump of cardiac sarcoplasmic reticulum［J］. Biochim Biophys Acta, 1991, 1070(5): 83-91. ［9］ Plein A, Fantin A, Ruhrberg C. Neuropilin regulation of angiogenesis, arteriogenesis, and vascular permeability［J］. Microcirculation, 2014, 21(4): 315-323. DOI: 10.1111/micc.12124. ［10］ Kawasaki T, Kitsukawa T, Bekku Y, et al. A requirement for neuropilin1 in embryonic vessel formation［J］. Development, 1999, 126(21): 4895-4902. ［11］ Eichmann A, Makinen T, Alitalo K. Neural guidance molecules regulate vascular remodeling and vessel navigation［J］. Genes Dev, 2005, 19(9): 1013-1021. DOI: 10.1101/gad.1305405. ［12］ Staton CA, Kumar I, Reed MW, et al. Neuropilins in physiological and pathological angiogenesis［J］. J Pathol, 2007, 212(3): 237-248. DOI: 10.1002/path.2182. ［13］ Bergé M, Allanic D, Bonnin P, et al. Neuropilin1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodeling［J］. J Hepatol, 2011, 55(4): 866-875. DOI: 10.1016/j.jhep.2011.01.033. ［14］ He Z, TessierLavigne M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin Ⅲ［J］. Cell, 1997, 90(4): 739-751. ［15］ Zhang Y, Liu P, Jiang Y, et al. High expression of neuropilin1 associates with unfavorable clinicopathological features in hepatocellular carcinoma［J］. Pathol Oncol Res, 2016, 22(2): 367-375. DOI: 10.1007/s122530150003z. ［16］ Liu Q, Xu Y, Wei S, et al. miRNA148b suppresses hepatic cancer stem cell by targeting neuropilin1［J］. Biosci Rep, 2015, 35(4). pii: e00229. DOI: 10.1042/BSR20150084. ［17］ Xu J, Xia J. NRP1 silencing suppresses hepatocellular carcinoma cell growth in vitro and in vivo［J］. Exp Ther Med, 2013, 5(1): 150-154. DOI: 10.3892/etm.2012.803. ［18］ Raskopf E, Vogt A, Decker G, et al. Combination of hypoxia and RNAinterference targeting VEGF induces apoptosis in hepatoma cells via autocrine mechanisms［J］. Curr Pharm Biotechnol, 2012, 13(11): 2290-2298. ［19］ Elpek G. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update［J］. World J Gastroenterol, 2014, 20(23): 7260-7276. DOI: 10.3748/wjg.v20.i23.7260. ［20］ Kukla M. Angiogenesis: a phenomenon which aggravates chronic liver disease progression［J］. Hepatol Int, 2013, 7(1): 4-12. DOI: 10.1007/s1207201293912. ［21］ Bergé M, Allanic D, Bonnin P, et al. Neuropilin1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodeling［J］. J Hepatol, 2011, 55(4): 866-875. DOI: 10.1016/j.jhep.2011.01.033.

[1]	Liu Bohan, Huang Junxing. Research progress of solute carriers related genes in malignant tumors [J]. Journal of International Oncology, 2023, 50(5): 280-284.
[2]	Xu Qiuyue, Ma Xianmei, Yue Qi. Immunotherapy for endometrial carcinoma based on molecular typing [J]. Journal of International Oncology, 2022, 49(11): 700-704.
[3]	Zhang Jing, Huang Shouguo, Xia Ying. Mechanism study of CeRNA regulatory network mediating malignant tumor phenotype [J]. Journal of International Oncology, 2021, 48(9): 544-548.
[4]	Zhao Congxuan, Yu Tao. Mining and prediction of glioma-related genes [J]. Journal of International Oncology, 2020, 47(5): 293-296.
[5]	Wang Zhao, Wang Yingnan, Ni Jixiang, Zhu Jing. Expression and role of Hippo signaling pathway in non-small cell lung cancer [J]. Journal of International Oncology, 2019, 46(4): 239-242.
[6]	Hu Yanhong, Zhao Guofeng, Wang Donghai. Clinical significance of preoperative platelet count in laryngeal squamous cell carcinoma prognosis [J]. Journal of International Oncology, 2019, 46(2): 82-86.
[7]	Deng Siyuan, He De. Expression of miR-490 in malignant tumors and its molecular mechanism [J]. Journal of International Oncology, 2019, 46(10): 601-604.
[8]	LIU Hou-Jie, WAN Jing-Hai. Molecular mechanism in malignant progression of meningioma [J]. Journal of International Oncology, 2018, 45(8): 494-498.
[9]	Shen Kai, Shao Fang, Feng Tongbao, Qi Chunjian. Role of microRNA-373 in tumor [J]. Journal of International Oncology, 2018, 45(6): 355-357.
[10]	ZHANG Xiang, ZHUANG Rui. Influences of platelet distribution width on the prognosis of patients with nasopharyngeal cancer [J]. Journal of International Oncology, 2018, 45(5): 257-261.
[11]	ZHENG Pan-Chan, SUN Xiao, WANG Li-Hua. Circular RNA and its application in gynecological carcinoma [J]. Journal of International Oncology, 2018, 45(5): 308-311.
[12]	Yuan Jiayi, He Hengjing, Bi Yaqiong, Guo Zixin, Xiao Yu, Li Sheng. Prognostic value analysis of TOP2A gene expression for bladder cancer [J]. Journal of International Oncology, 2018, 45(1): 22-.
[13]	Lu Jiao, Liu Dandan. Advances of ecotropic viral integration site 1 gene in acute lymphoblastic leukemia [J]. Journal of International Oncology, 2017, 44(8): 626-628.
[14]	Ke Jianbo, Ling Zhiqiang, Shang Jinbiao. Research progress of miR-151-5p in tumor [J]. Journal of International Oncology, 2017, 44(6): 445-.
[15]	ZHOU Shu, SHEN Na, CHENG Fan-Jun. Competing endogenous RNA and tumor pathological mechanism [J]. Journal of International Oncology, 2017, 44(2): 115-117.